GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albany Molecular Research Inc (NAS:AMRI) » Definitions » EV-to-EBIT

Albany Molecular Research (Albany Molecular Research) EV-to-EBIT : -67.47 (As of May. 11, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Albany Molecular Research EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Albany Molecular Research's Enterprise Value is $937.4 Mil. Albany Molecular Research's EBIT for the trailing twelve months (TTM) ended in Jun. 2017 was $-13.9 Mil. Therefore, Albany Molecular Research's EV-to-EBIT for today is -67.47.

The historical rank and industry rank for Albany Molecular Research's EV-to-EBIT or its related term are showing as below:

AMRI's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 9.43
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Albany Molecular Research's Enterprise Value for the quarter that ended in Jun. 2017 was $1,538.0 Mil. Albany Molecular Research's EBIT for the trailing twelve months (TTM) ended in Jun. 2017 was $-13.9 Mil. Albany Molecular Research's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2017 was -0.90%.


Albany Molecular Research EV-to-EBIT Historical Data

The historical data trend for Albany Molecular Research's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albany Molecular Research EV-to-EBIT Chart

Albany Molecular Research Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 210.48 12.55 111.91 76.71 -115.12

Albany Molecular Research Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 111.96 -136.56 -115.12 -205.82 -110.69

Competitive Comparison of Albany Molecular Research's EV-to-EBIT

For the Biotechnology subindustry, Albany Molecular Research's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Albany Molecular Research's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albany Molecular Research's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Albany Molecular Research's EV-to-EBIT falls into.



Albany Molecular Research EV-to-EBIT Calculation

Albany Molecular Research's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=937.410/-13.894
=-67.47

Albany Molecular Research's current Enterprise Value is $937.4 Mil.
Albany Molecular Research's EBIT for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Albany Molecular Research  (NAS:AMRI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Albany Molecular Research's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2017 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2017 ) =EBIT / Enterprise Value (Q: Jun. 2017 )
=-13.894/1538.0331
=-0.90 %

Albany Molecular Research's Enterprise Value for the quarter that ended in Jun. 2017 was $1,538.0 Mil.
Albany Molecular Research's EBIT for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Albany Molecular Research EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Albany Molecular Research's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Albany Molecular Research (Albany Molecular Research) Business Description

Traded in Other Exchanges
N/A
Address
Albany Molecular Research provides research services to pharmaceutical, biotechnology, and chemical companies. The company offers services like design and modification of potential lead compounds, purification technique development, quality control, bulk ingredient stability studies, and regulatory documentation preparation. The company has entered into collaborative agreements with companies like Eli Lilly and Cambrex. Albany's acquisition of Organichem provided the company with commercial manufacturing capabilities.
Executives
Anthony J Maddaluna director PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
Felicia I Ladin officer: SVP, Treasurer & CFO 26 CORPORATE CIRCLE, ALBANY NY 12203
David H Deming director C/O BETTER FOR YOU WELLNESS, INC., 1349 EAST BROAD ST, COLUMBUS OH 43205
William S Marth director, officer: President and CEO 236 GROVE STREET, WELLESLEY MA 02482
Lori M. Henderson officer: SVP, Secretary & Gen Counsel MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Una S Ryan director 329 HAMMOND STREET, CHESTNUT HILL MA 02467
Veronica Gh Jordan director C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Gabriel Leung director C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Michael A Luther officer: Senior VP, Discovery Services 21 CORPORATE CIRCLE, ALBANY NY 12203
Mark T Frost officer: Chief Financial Officer 21 CORPORATE CIRCLE, PO BOX 15098, ALBANY NY 12033-5098
David P Waldek officer: Chief Financial Officer ALBANY MOLECULAR RESEARCH INC, 21 CORPORATE CIRCLE PO BOX 15098, ALBANY NY 12212-5098

Albany Molecular Research (Albany Molecular Research) Headlines

No Headlines